NASH vs Fatty Liver: Differences and UK Treatment

NASH vs fatty liver is a distinction that matters clinically: while both involve fat accumulation in the liver, they carry very different risks. Simple fatty liver (steatosis) is common and often harmless, whereas non-alcoholic steatohepatitis (NASH) involves active inflammation, liver cell injury, and a significantly higher risk of progressing to cirrhosis or liver failure. Understanding the difference helps you recognise warning signs, seek timely assessment, and take steps to protect your liver health. This article explains how the two conditions differ, how NASH is diagnosed on the NHS, and what treatment and lifestyle options are available in the UK.

What is the difference between fatty liver and NASH?

Fatty liver involves fat accumulation in liver cells without significant inflammation, while NASH additionally features active inflammation, hepatocyte ballooning, and often early fibrosis, carrying a meaningfully higher risk of cirrhosis and liver failure.

Fatty liver (steatosis) and non-alcoholic steatohepatitis (NASH) are distinct stages of the same underlying liver disease, with NASH representing a more serious, inflammatory form. Simple fatty liver, now more commonly called metabolic dysfunction-associated steatotic liver disease (MASLD), describes the accumulation of fat in liver cells without significant inflammation or cell damage. It is very common in the UK, and in most people it causes no lasting harm.

NASH, now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), is defined by the presence of fat alongside active liver cell inflammation, hepatocyte injury (a pattern called ballooning), and often early scarring (fibrosis). This distinction matters clinically because NASH carries a meaningfully higher risk of progressing to cirrhosis, liver failure, and hepatocellular carcinoma compared with simple fatty liver.^[1][2]

The terminology in this field has been updated by international liver societies, including the British Society of Gastroenterology (BSG) and the British Association for the Study of the Liver (BASL), to reflect the close link with metabolic risk factors such as obesity, type 2 diabetes, hypertension, and dyslipidaemia. You may encounter both the older terms (NAFLD, NASH) and the newer ones (MASLD, MASH) in clinical correspondence and NHS letters. For clarity, this article uses NASH and fatty liver throughout, as these remain the most widely recognised terms in everyday clinical practice.

How does simple fatty liver progress to NASH?

Fatty liver progresses to NASH when accumulated fat triggers oxidative stress, insulin resistance, and liver inflammation; metabolic risk factors such as obesity and type 2 diabetes accelerate this process, though progression is not inevitable.

Simple fatty liver progresses to NASH when accumulated fat triggers oxidative stress, mitochondrial dysfunction, and an inflammatory cascade within liver tissue. The precise mechanisms are not fully understood, but a widely accepted model involves a combination of insulin resistance, lipotoxicity (damage caused by excess fatty acids), gut microbiome changes, and genetic susceptibility. Variants in genes such as PNPLA3 and TM6SF2 are associated with increased individual risk of progression, though these are not yet routinely tested in NHS practice.^[2][3]

Metabolic risk factors play a central role. People living with obesity, particularly central adiposity, type 2 diabetes, or metabolic syndrome, are at substantially greater risk of developing NASH and of progressing more rapidly to fibrosis. Rapid weight loss in certain clinical contexts (for example, very low calorie diets or following bariatric surgery without adequate monitoring), certain medicines (including corticosteroids and some antiretrovirals, as associations rather than proven direct causes), and high fructose intake have also been linked to accelerated liver injury.

Once NASH is established, fibrosis can develop and worsen over time. Fibrosis is staged from F0 (none) to F4 (cirrhosis).^[7][8] Not everyone with NASH progresses, and the rate of progression varies considerably between individuals. Some people remain at an early fibrosis stage for decades, while others advance more quickly, particularly if metabolic risk factors are poorly controlled. Alcohol consumption, even at moderate levels, can compound liver injury and should be minimised in anyone with known liver disease.

Importantly, progression is not inevitable or irreversible. Evidence from histology-based studies and summarised in EASL and BSG guidance consistently shows that sustained lifestyle modification can halt and, in some cases, reverse fibrosis, which is why early identification and intervention are clinically important.

What symptoms and signs should prompt you to see a GP?

Most people with fatty liver or early NASH have no symptoms; see your GP if you have persistent fatigue, upper right abdominal discomfort, or elevated liver enzymes, and seek urgent care for jaundice, abdominal swelling, or vomiting blood.

Most people with simple fatty liver or early NASH have no symptoms at all, which is why the conditions are frequently discovered incidentally during blood tests or abdominal ultrasound arranged for another reason. When symptoms do occur, they tend to be non-specific and easy to attribute to other causes.

You should make a routine appointment with your GP if you experience any of the following:

• Persistent fatigue or low energy that is unexplained by other factors

• A dull ache or discomfort in the upper right abdomen

• Unexplained weight loss

• Mildly elevated liver enzymes (ALT or AST) flagged on a blood test result letter

More urgent symptoms may indicate advanced liver disease or cirrhosis and warrant prompt medical review. Contact your GP as soon as possible, or call NHS 111 for advice, if you notice:

• Yellowing of the skin or whites of the eyes (jaundice)

• Swelling of the abdomen (ascites) or ankles

• Confusion or difficulty concentrating (which can indicate hepatic encephalopathy)

• Vomiting blood or passing very dark, tarry stools

For the last two symptoms in particular, call 999 or go to your nearest A&E immediately, as these can represent life-threatening complications of cirrhosis.

NICE guidance (NG49) does not recommend routine population screening for fatty liver disease.^[5][20] However, if you have risk factors such as type 2 diabetes, obesity, or metabolic syndrome and your GP finds abnormal liver enzymes or incidental steatosis on imaging, further assessment and risk stratification are recommended. If you have these risk factors, it is worth discussing liver health proactively with your GP.

How is NASH diagnosed on the NHS?

NHS diagnosis begins with liver function tests and the FIB-4 index in primary care; indeterminate or high scores prompt referral for ELF testing or FibroScan, with liver biopsy reserved for cases where non-invasive results are inconclusive.

NASH is diagnosed through a combination of blood tests, imaging, and in some cases liver biopsy, as no single non-invasive test can confirm the diagnosis with certainty. Your GP will typically begin with liver function tests (LFTs), a fasting lipid profile, HbA1c, and a full blood count. Elevated alanine aminotransferase (ALT) is a common but non-specific finding; normal LFTs do not exclude significant liver disease. Other causes of abnormal liver tests, including alcohol use, viral hepatitis, autoimmune liver disease, and iron overload, are assessed and excluded in parallel.

NICE guidance (NG49) recommends a stepwise approach to fibrosis risk stratification. In primary care, the FIB-4 index (calculated from age, ALT, AST, and platelet count) or the NAFLD Fibrosis Score is used as a first-line tool. A low score is reassuring, while an indeterminate or high score prompts referral to a hepatology or gastroenterology service. In secondary care, the Enhanced Liver Fibrosis (ELF) blood test or transient elastography (FibroScan) is used to refine the assessment, with age-specific cut-offs applied to FIB-4 to reduce false positives in older adults.^[5][7]

Ultrasound of the liver is widely available on the NHS and can detect moderate to severe steatosis, but it cannot reliably distinguish simple fatty liver from NASH, nor can it accurately stage fibrosis. Transient elastography measures liver stiffness as a proxy for fibrosis and is increasingly available in secondary care.

Liver biopsy remains the definitive diagnostic test for NASH, as it is the only method that can confirm the presence of inflammation and ballooning alongside fat. However, it is invasive and carries a small risk of complications, so it is reserved for cases where non-invasive tests are inconclusive and the result would change clinical management. Your hepatologist will discuss whether biopsy is appropriate in your individual case.

Can fatty liver or NASH be reversed with lifestyle changes?

Yes, both conditions can be significantly improved or reversed; a weight loss of 7 to 10% is associated with histological improvement in NASH, and the Mediterranean diet alongside regular physical activity has the strongest evidence base.

Yes, both fatty liver and NASH can be significantly improved, and in many cases reversed, through sustained lifestyle changes, particularly weight loss. This is one of the most robustly evidenced findings in hepatology, supported by histology-based studies and summarised in EASL and BSG clinical guidance. A weight loss of around 5% of body weight has been shown to reduce liver fat, while a loss of 7 to 10% is associated with histological improvement in NASH, including reductions in inflammation and ballooning.^[2][5] Weight loss of 10% or more has been linked to regression of fibrosis in some studies.^[9][19]

The most effective dietary approach is one that creates a sustained calorie deficit while being nutritionally balanced. The Mediterranean diet, which emphasises vegetables, legumes, wholegrains, fish, and olive oil while limiting red meat, refined carbohydrates, and ultra-processed foods, has the strongest evidence base for liver health in MASLD and MASH, as reflected in EASL guidance.^[2][3] Fructose-containing drinks, including fruit juices and sugar-sweetened beverages, should be minimised, as fructose is directly metabolised in the liver and promotes fat accumulation.

Regular physical activity independently improves liver fat and insulin sensitivity, even without significant weight loss. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have demonstrated benefit. UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[10][11]

Alcohol should be kept to a minimum. While NASH is defined as occurring in the absence of significant alcohol use, even low to moderate alcohol intake can worsen liver inflammation and accelerate fibrosis in people with pre-existing liver disease. The UK Chief Medical Officers' low-risk drinking guidelines advise no more than 14 units per week, spread across three or more days, with some alcohol-free days each week.

For people who struggle to achieve sufficient weight loss through diet and exercise alone, referral to a structured weight management programme via the NHS may be appropriate. Your GP can advise on local services.

What treatment options are available in the UK for NASH?

Lifestyle modification is the cornerstone of NASH management in the UK; no medicine is currently licensed specifically for NASH, but weight management medicines such as semaglutide or tirzepatide may be considered for eligible patients with obesity.

Lifestyle modification remains the cornerstone of NASH management in the UK, but pharmacological and procedural options are increasingly available for people who do not achieve adequate improvement through diet and exercise alone. At the time of writing, no medicine holds a UK marketing authorisation specifically for the treatment of NASH or MASH, though this is a rapidly evolving area and the licensing position should be verified with current MHRA or EMC sources.

For people with obesity and NASH, NICE-recommended weight management medicines may be considered as part of a broader treatment plan. Semaglutide (Wegovy, available as a subcutaneous injection or as Wegovy 25 mg tablets, the oral formulation authorised by the MHRA in June 2026) and tirzepatide (Mounjaro, a dual GIP and GLP-1 receptor agonist authorised by the MHRA for both type 2 diabetes and chronic weight management) have both demonstrated reductions in liver fat and markers of liver inflammation in clinical trials.^[13] These medicines are not currently licensed for NASH specifically; their relevance to liver disease management arises from their effects on body weight and metabolic risk factors, which are the primary drivers of NASH. Eligibility for NHS prescribing is determined by local Integrated Care Boards (ICBs) in line with NICE guidance, and not all patients will qualify. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro is one option a prescriber may consider after assessment and only where it is clinically appropriate.

Bariatric surgery is an option for people with severe obesity and NASH who have not responded to other interventions. Evidence shows that surgically induced weight loss can lead to substantial histological improvement, including fibrosis regression. NICE guidance on bariatric surgery sets out eligibility criteria.

For people with advanced fibrosis or cirrhosis, specialist hepatology follow-up is essential, including surveillance for hepatocellular carcinoma and, in end-stage disease, assessment for liver transplantation. Suspected side effects from any medicine used in this context can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Draft Reflection Paper on Regulatory Requirements for Development of Medicinal Products for Chronic Non-Infectious Liver Diseases (PBC, PSC, NASH).
2. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
3. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (second record).
4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
5. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49).
6. Metabolic dysfunction-associated steatotic liver disease (NG49) — consultation comments and responses.
7. NICE Diagnostics Assessment Programme — NAFLD/MASLD overview document.
8. Non-alcoholic fatty liver disease (NAFLD).
9. Total body weight loss of ≥10% is associated with regression of fibrosis in NASH.
10. UK Chief Medical Officers' Physical Activity Guidelines.
11. Physical activity guidelines for adults aged 19 to 64.
12. Alcohol consumption: advice on low risk drinking.
13. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide Wegovy 25 mg).
14. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
15. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
16. Semaglutide and Tirzepatide for the treatment of MASH.
17. Efficacy of GLP-1-based Therapies on MASLD and MASH: A Systematic Review and Meta-analysis.
18. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis.
19. Weight Loss as a Determinant of Histological Improvement in MASLD in People With Obesity: A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.
20. Quality standards for the management of non-alcoholic fatty liver disease.

Frequently Asked Questions